论文部分内容阅读
异基因造血干细胞移植(Allo-HSCT)是某些血液系统恶性疾病惟一有望治愈的手段,也是某些血液系统非恶性疾病的重要治疗手段。HLA相合同胞供者是Allo-HSCT首选的供者来源,但是只有部分患者可以找到相合的同胞供者。因此,寻找合适的非血缘供者就变得十分重要。近年来,随着移植技术方案的成熟和支持治疗的进步,移植现状已获得明显的改善,非血缘供者造血干细胞移植疗效已达到了与同胞供者移植接近的水平。
Allo-HSCT is the only hopeful cure for certain hematological malignancies and is an important treatment for some non-malignant diseases of the hematological system. HLA-matched sibling donors are the preferred source of Allo-HSCT donors, but only a subset of patients can find compatible sibling donors. Therefore, to find the right non-blood donor becomes very important. In recent years, with the maturity of transplant technology and advances in supportive care, the status of transplantation has been significantly improved. The effect of non-blood donor hematopoietic stem cell transplantation has reached a level close to that of fellow donors.